DDInter1042 DDInter581
Leuprolide is a synthetic 9-residue peptide analogue of gonadotropin-releasing hormone (GnRH). Unlike the endogenous decapeptide GnRH, leuprolide contains a single D-amino acid (D-leucyl) residue, which helps to increase its circulating half-life from three to four minutes to approximately three hours. As a GnRH mimic, leuprolide is capable of binding to the GnRH receptor (GnRHR) and inducing downstream modulation of both gonadotropin hormone and sex steroid levels. Prolonged activation of GnRHR results in significant downregulation of sex steroid levels, which is primarily responsible for the clinical efficacy of leuprolide in diverse conditions, including advanced prostate cancer, endometriosis, and central precocious puberty.[A203126, A203132] Leuprolide was first approved in 1985 as a daily subcutaneous injection under the tradename
Dolasetron is an antinauseant and antiemetic agent indicated for the prevention of nausea and vomiting associated with moderately-emetogenic cancer chemotherapy and for the prevention of postoperative nausea and vomiting. Dolasetron is a highly specific and selective serotonin 5-HT3 receptor antagonist. This drug is not shown to have activity at other known serotonin receptors, and has low affinity for dopamine receptors.
Dolasetron {u} (Compound) resembles {v} (Compound) Hyoscyamine
Dolasetron {u} (Compound) resembles {v} (Compound) Atropine
Dolasetron {u} (Compound) binds {v} (Gene) CYP2D6
Dolasetron {u} (Compound) upregulates {v} (Gene) UBQLN2
Dolasetron {u} (Compound) is included by {v} (Pharmacologic Class) Serotonin 3 Receptor Antagonists
Dolasetron {u} (Compound) causes {v} (Side Effect) Oliguria
Dolasetron {u} may cause a minor interaction that can limit clinical effects when taken with {v} Cimetidine
Dolasetron {u} may cause a minor interaction that can limit clinical effects when taken with {v} Rifampicin
Dolasetron {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Oxycodone
Dolasetron {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Donepezil
Dolasetron (Compound) resembles Hyoscyamine (Compound)
Dolasetron (Compound) resembles Atropine (Compound)
Dolasetron (Compound) binds CYP2D6 (Gene)
Dolasetron (Compound) upregulates UBQLN2 (Gene)
Dolasetron (Compound) is included by Serotonin 3 Receptor Antagonists (Pharmacologic Class)
Dolasetron (Compound) causes Oliguria (Side Effect)
Dolasetron may cause a minor interaction that can limit clinical effects when taken with Cimetidine
Dolasetron may cause a minor interaction that can limit clinical effects when taken with Rifampicin
Dolasetron may cause a moderate interaction that could exacerbate diseases when taken with Oxycodone
Dolasetron may cause a moderate interaction that could exacerbate diseases when taken with Donepezil